ALDX Investors Have Opportunity to Join Aldeyra Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Core Viewpoint - The Schall Law Firm is investigating Aldeyra Therapeutics, Inc. for potential violations of securities laws following a significant drop in share price after the FDA issued a Complete Response Letter regarding the company's drug reproxalap [1][2]. Group 1: Investigation Details - The investigation centers on whether Aldeyra made false or misleading statements or failed to disclose critical information to investors [2]. - On April 3, 2025, Aldeyra announced that the FDA's Complete Response Letter indicated that the NDA for reproxalap "failed to demonstrate efficacy in adequate and well controlled studies in treating ocular symptoms associated with dry eyes" [2]. - Despite Aldeyra's claims of "uniquely supportive" clinical trial data, the FDA expressed concerns regarding the trial data submitted as part of the NDA [2]. Group 2: Market Impact - Following the FDA's announcement, Aldeyra's shares plummeted by nearly 75% during trading on the same day [2].